全文获取类型
收费全文 | 20820篇 |
免费 | 1899篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 234篇 |
儿科学 | 668篇 |
妇产科学 | 391篇 |
基础医学 | 2913篇 |
口腔科学 | 322篇 |
临床医学 | 2240篇 |
内科学 | 4124篇 |
皮肤病学 | 309篇 |
神经病学 | 1870篇 |
特种医学 | 642篇 |
外国民族医学 | 3篇 |
外科学 | 2649篇 |
综合类 | 484篇 |
一般理论 | 14篇 |
预防医学 | 2165篇 |
眼科学 | 723篇 |
药学 | 1570篇 |
中国医学 | 22篇 |
肿瘤学 | 1417篇 |
出版年
2021年 | 284篇 |
2020年 | 240篇 |
2019年 | 363篇 |
2018年 | 376篇 |
2017年 | 287篇 |
2016年 | 338篇 |
2015年 | 399篇 |
2014年 | 558篇 |
2013年 | 823篇 |
2012年 | 1220篇 |
2011年 | 1301篇 |
2010年 | 636篇 |
2009年 | 668篇 |
2008年 | 1088篇 |
2007年 | 1234篇 |
2006年 | 1173篇 |
2005年 | 1193篇 |
2004年 | 1156篇 |
2003年 | 987篇 |
2002年 | 986篇 |
2001年 | 444篇 |
2000年 | 463篇 |
1999年 | 467篇 |
1998年 | 267篇 |
1997年 | 195篇 |
1996年 | 200篇 |
1995年 | 200篇 |
1994年 | 170篇 |
1993年 | 155篇 |
1992年 | 306篇 |
1991年 | 309篇 |
1990年 | 300篇 |
1989年 | 293篇 |
1988年 | 263篇 |
1987年 | 248篇 |
1986年 | 276篇 |
1985年 | 232篇 |
1984年 | 204篇 |
1983年 | 156篇 |
1982年 | 158篇 |
1981年 | 124篇 |
1980年 | 121篇 |
1979年 | 193篇 |
1978年 | 143篇 |
1977年 | 108篇 |
1976年 | 100篇 |
1975年 | 100篇 |
1974年 | 113篇 |
1973年 | 131篇 |
1972年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 156 毫秒
1.
2.
3.
4.
5.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献6.
7.
8.
Nimrat Chatterjee Sanjay D'Souza Mohammad Shabab Cynthia A. Harris Gerard J. Hilinski Gregory L. Verdine Graham C. Walker 《Environmental and molecular mutagenesis》2020,61(8):830-836
Stapled α-helical RIR (Rev1-interacting region) peptides of DNA POL κ bind more effectively to the RIR-interface of the C-terminal recruitment domain of the translesion synthesis DNA polymerase Rev1 than unstapled peptide. The tightest-binding stapled peptide translocates into cells and enhances the cytotoxicity of DNA damaging agents while reducing mutagenesis. Drugs with these characteristics could potentially serve as adjuvants to improve chemotherapy and reduce acquired resistance by inhibiting Rev1-dependent mutagenic translesion synthesis. 相似文献
9.
Tuong L. Nguyen Shuai Li Gillian S. Dite Ye K. Aung Christopher F. Evans Ho N. Trinh Laura Baglietto Jennifer Stone Yun-Mi Song Joohon Sung Dallas R. English Mark A. Jenkins Pierre-Antoine Dugué Roger L. Milne Melissa C. Southey Graham G. Giles Malcolm C. Pike John L. Hopper 《International journal of cancer. Journal international du cancer》2020,147(2):375-382
Interval breast cancers (those diagnosed between recommended mammography screens) generally have poorer outcomes and are more common among women with dense breasts. We aimed to develop a risk model for interval breast cancer. We conducted a nested case–control study within the Melbourne Collaborative Cohort Study involving 168 interval breast cancer patients and 498 matched control subjects. We measured breast density using the CUMULUS software. We recorded first-degree family history by questionnaire, measured body mass index (BMI) and calculated age-adjusted breast tissue aging, a novel measure of exposure to estrogen and progesterone based on the Pike model. We fitted conditional logistic regression to estimate odds ratio (OR) or odds ratio per adjusted standard deviation (OPERA) and calculated the area under the receiver operating characteristic curve (AUC). The stronger risk associations were for unadjusted percent breast density (OPERA = 1.99; AUC = 0.66), more so after adjusting for age and BMI (OPERA = 2.26; AUC = 0.70), and for family history (OR = 2.70; AUC = 0.56). When the latter two factors and their multiplicative interactions with age-adjusted breast tissue aging (p = 0.01 and 0.02, respectively) were fitted, the AUC was 0.73 (95% CI 0.69–0.77), equivalent to a ninefold interquartile risk ratio. In summary, compared with using dense breasts alone, risk discrimination for interval breast cancers could be doubled by instead using breast density, BMI, family history and hormonal exposure. This would also give women with dense breasts, and their physicians, more information about the major consequence of having dense breasts—an increased risk of developing an interval breast cancer. 相似文献
10.
Jay A. Graham Julia Torabi Maria Ajaimy Enver Akalin Luz E. Liriano Yorg Azzi Cindy Pynadath Stuart M. Greenstein Doctor Y. Goldstein Amy S. Fox Jeffery M. Weiss Tia P. Powell John F. Reinus Milan M. Kinkhabwala Juan P. Rocca 《Clinical transplantation》2020,34(4):e13833
The advent of direct-acting antivirals (DAAs) has provided the impetus to transplant kidneys from hepatitis C virus-positive donors into uninfected recipients (D+/R−). Thirty D+/R− patients received DAA treatment. Sustained virologic response (SVR12) was defined as an undetectable viral load in 12 weeks after treatment. An age-matched cohort of uninfected donor and recipient pairs (D−/R−) transplanted during same time period was used for comparison. The median day of viral detection was postoperative day (POD) 2. The detection of viremia in D+/R− patients was 100%. The initial median viral load was 531 copies/μL (range: 10-1 × 108 copies/μL) with a median peak viral load of 3.4 × 105 copies/μL (range: 804-1.0 × 108 copies/μL). DAAs were initiated on median POD 9 (range: 5-41 days). All 30 patients had confirmed SVR12. During a median follow-up of 10 months, patient and graft survival was 100%, and acute rejection was 6.6% with no major adverse events related to DAA treatment. Delayed graft function was significantly decreased in D+/R− patients as compared to the age-matched cohort (27% vs 60%; P = .01). D+/R− transplantation offers patients an alternative strategy to increase access. 相似文献